Abstract:The PI3K/AKT/mTOR pathway is one of the most common dysregulated signaling cascade responses in human cancers, playing a crucial role in cell proliferation and angiogenesis. Therefore, the development of anticancer drugs targeting the PI3K and mTOR pathways has become a research hotspot in cancer treatment. In this study, the PI3K selective inhibitor GDC-0941 was selected as a lead compound, and 28 thiophenyl-triazine derivatives with aromatic urea structures were synthesized based on scaffold hopping, serving as a novel class of PI3K/mTOR dual inhibitors. The most promising compound Y-2 was obtained through antiproliferative activity evaluation, kinase inhibition, and toxicity assays. The results showed that Y-2 demonstrated potential inhibitory effects on both PI3K kinase and mTOR kinase, with IC50 values of 171.4 and 10.2 nM, respectively. The inhibitory effect of Y-2 on mTOR kinase was 52 times greater than that of the positive drug GDC-0941. Subsequently, the antitumor activity of Y-2 was verified through pharmacological experiments such as AO staining, cell apoptosis, scratch assays, and cell colony formation. The antitumor mechanism of Y-2 was further investigated through JC-1 experiments, real-time quantitative PCR, and Western blot analysis. Based on the above experiments, Y-2 can be identified as a potent PI3K/mTOR dual inhibitor for cancer treatment. A series of thiophene-triazine derivatives with aromatic urea structures were designed and synthesized based on a scaffold hopping approach. GDC-0941 was selected as the lead compound, and the active group of PKI-587 was introduced to design a novel class of PI3K/mTOR dual inhibitors. Pharmacological experiments have indicated that Y-2 can be identified as a novel PI3K/mTOR dual inhibitor for cancer therapy.image

Discovery of Novel PI3K/CDK2 Dual Inhibitor Based on 7-Azaindole Derivatives As a Promising Strategy for Triple-Negative Breast Cancer Therapy

Discovery and identification of a novel PI3K inhibitor with enhanced CDK2 inhibition for the treatment of triple negative breast cancer

Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer.

Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity

Development of Anti-Breast Cancer PI3K Inhibitors Based on 7-Azaindole Derivatives Through Scaffold Hopping: Design, Synthesis and in Vitro Biological Evaluation

Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors As a Promising Strategy for Cancer Therapy

Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53

Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer

Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer

Discovery of a Tetrahydroisoquinoline-Based CDK9-cyclin T1 Protein–protein Interaction Inhibitor As an Anti-Proliferative and Anti-Migration Agent Against Triple-Negative Breast Cancer Cells

Design, Synthesis, and Biological Evaluation of Novel 4,4′-Bipyridine Derivatives Acting As CDK9-Cyclin T1 Protein-Protein Interaction Inhibitors Against Triple-Negative Breast Cancer

Discovery of Novel Thiophene [2,3-D] Pyrimidine–thiazole Derivative As Promising MNK Inhibitor to Treat Breast Cancer

Discovery of Dual CDK6/BRD4 Inhibitor Inducing Apoptosis and Increasing the Sensitivity of Ferroptosis in Triple-Negative Breast Cancer.

Structure-Based Design of 2-Aminopurine Derivatives As CDK2 Inhibitors for Triple-Negative Breast Cancer

Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA

Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea Derivatives Against Breast Cancer by Inhibiting PI3K/Akt/mTOR and Hedgehog Signalings

Discovery and SARs of 5-Chloro-n4-phenyl-n2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives As Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity

Discovery of Novel Potent PI3K/mTOR Dual-Target Inhibitors Based on Scaffold Hopping: Design, Synthesis, and Antiproliferative Activity

Discovery of Novel PARP/PI3K Dual Inhibitors with High Efficiency Against BRCA-proficient Triple Negative Breast Cancer.

Discovery of 2-(aminopyrimidin-5-yl)-4-(morpholin-4-yl)-6- substituted triazine as PI3K and BRAF dual inhibitor.

Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives As PI3K Inhibitors with Potent Activity.